Key Points

• A recent pilot study suggests psilocybin therapy may reduce symptoms of post-treatment Lyme disease by 40%.

•The treatment, combined with psychological support, was found to be safe and well-tolerated in the study participants.

•Improvements in mood, fatigue, and pain were observed to last for up to six months after treatment.

•For a condition with no currently accepted treatments, psilocybin-assisted therapy presents a promising area of research.

•These are early findings, and larger, controlled trials are necessary to confirm the benefits for PTLD.

10-20% of Lyme disease patients develop persistent symptoms, and life can become a daily struggle with pain, fatigue, and cognitive issues long after the initial infection is gone. This condition, known as Post-Treatment Lyme Disease (PTLD), has long puzzled doctors and left patients with few effective treatment options. 

However, a groundbreaking pilot study from Johns Hopkins University suggests a surprising new avenue for relief: psilocybin, the psychoactive compound found in certain mushrooms. The study found that psilocybin-assisted therapy could be a safe and effective future treatment for the debilitating symptoms of PTLD, offering a beacon of hope for those who have been suffering in silence (1).

This emerging research opens up a crucial conversation about the potential of psychedelic medicine to address complex, chronic conditions that have stumped traditional medicine. For individuals in Texas and beyond who are navigating the challenges of PTLD, understanding these developments is a critical first step.

 This article will break down what the science says, what it means for the future of Lyme treatment, and how to approach this information with both hope and caution.

What is Post-Treatment Lyme Disease Syndrome?

Post-Treatment Lyme Disease Syndrome (PTLDS) is a condition where patients continue to experience symptoms like severe fatigue, muscle and joint pain, cognitive problems (often called "brain fog"), and mood disturbances for more than six months after completing standard antibiotic treatment for Lyme disease (2). 

The exact cause is unknown, but theories point to ongoing inflammation or an autoimmune response triggered by the initial infection. This persistent suffering can severely impact a person's quality of life, making it difficult to work, maintain relationships, and engage in daily activities.

The challenge with PTLDS is the lack of a cure. Current approaches often focus on managing individual symptoms, but many patients find little relief, leading to a desperate search for alternatives. This is why the recent findings on psilocybin are so significant; they point toward a potential treatment that addresses the root of the suffering rather than just masking the symptoms.

How Was the Psilocybin Study for PTLDS Conducted?

The Johns Hopkins study was a small, open-label pilot study, meaning both the researchers and participants knew that psilocybin was being administered. It involved 20 adults with well-documented PTLD who were carefully screened for physical and psychological safety.

Over eight weeks, each participant received two doses of psilocybin in a controlled, therapeutic setting. These sessions were accompanied by extensive psychological support, including preparation visits before and integration sessions after each dose to help participants process their experiences (1).

Researchers tracked a wide range of outcomes, including overall symptom burden, quality of life, depression, fatigue, sleep, and pain levels using validated questionnaires. The goal was not just to see if symptoms improved, but to understand the safety and feasibility of this approach for a patient population often dealing with complex medical issues. 

The use of psychological support is a critical component of this therapeutic model, distinguishing it from recreational use and emphasizing the importance of a structured, supportive environment for healing.

What Were the Main Results of the Study?

The results were remarkable. On average, participants experienced a 40% reduction in their overall PTLD symptom burden, a benefit that was sustained for up to six months after the final session (1). 

This wasn't just a fleeting improvement. Patients reported significant and lasting reductions in depression, fatigue, sleep disturbance, and pain. Their mental and physical quality of life scores also showed substantial improvement, suggesting a holistic healing effect that went beyond any single symptom.

These findings are particularly compelling because the benefits did not diminish over time, which can sometimes happen with placebo effects in chronic illness trials. The sustained nature of the improvements suggests that the psilocybin-assisted therapy may have triggered a genuine reset in the brain's functioning, potentially by reducing the neuroinflammation associated with PTLD or by fostering new, healthier neural pathways. This aligns with other research showing psilocybin's ability to promote neuroplasticity (3).

Was the Psilocybin Treatment Safe?

Safety is a primary concern when exploring any new treatment, especially one involving a psychedelic compound. In this study, the psilocybin-assisted treatment was found to be safe and generally well-tolerated by the participants (1). 

There were no serious adverse events related to the psilocybin itself. The most common side effects were temporary and expected, including short-lived increases in blood pressure and heart rate, as well as headaches during or shortly after the dosing sessions.

It is crucial to emphasize that this safety profile was achieved under strict medical supervision with extensive psychological support. 

This is not a treatment that can or should be attempted on one's own. The structured environment and the presence of trained therapists are essential for navigating the powerful psychological experiences that can arise and for ensuring physical well-being. This study provides a model for how such treatments can be administered responsibly, paving the way for larger, more definitive trials.

What Do These Findings Mean for People with PTLDS?

For those living with the chronic, often invisible, burden of PTLD, these findings represent a significant source of hope. While this was a small, preliminary study, it provides the first clinical evidence that psilocybin-assisted therapy may offer meaningful and lasting relief from the multi-system symptoms of the condition. 

It suggests that we may be on the verge of a new paradigm for treating not just PTLD, but potentially other chronic inflammatory and pain conditions that have been difficult to manage.

This research may also help validate the experiences of patients whose suffering has often been dismissed or misunderstood. By identifying a biological basis for the therapeutic effects, it reinforces the understanding of PTLD as a real and serious medical condition. 

As you navigate your own health journey, whether it involves exploring Anxiety Therapy or seeking support for Trauma Therapy, staying informed about cutting-edge research like this is a powerful act of self-advocacy. 

For more on how psychedelics are being explored for difficult-to-treat pain conditions, you may find our post on psychedelics for cluster headaches to be a valuable read.

A Path Forward

The journey from a promising pilot study to a widely available, approved treatment is a long one. This research is a critical first step, but larger, randomized controlled trials are needed to confirm these benefits and to fully understand how psilocybin works to heal the complex symptoms of PTLD. 

However, for the millions of people affected by post-treatment Lyme disease, this study offers more than just data; it offers a tangible reason to be optimistic about the future.

If you are struggling with the lingering effects of Lyme disease or other chronic conditions, please know that you are not alone and that healing is possible. The path may not always be clear, but new research is constantly lighting the way forward. 

We encourage you to take the first step toward finding relief and reclaiming your life.Ready to explore a path toward healing? Contact us today to schedule a consultation and learn more about our compassionate, evidence-based approach to mental health and well-being.

About the Author

This article was written by Jeff Jones, a Licensed Professional Counselor (LPC) in Texas in practice 27 years. He is a 2024 graduate of the CIIS Center for Psychedelic Therapies and Research program. With a compassionate and evidence-based approach, he helps clients navigate life’s challenges and find a path toward healing.

Disclaimer

The information in this article, including discussions of psychedelic-assisted psychotherapy, is for informational purposes only. Psychedelic-assisted psychotherapy has not been approved by all regulatory agencies in the United States, and its safety and efficacy are still being established. This content is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

References

(1) Garcia-Romeu, A., Naudé, G. P., Rebman, A. W., So, S., Yaffe, A., Geithner, I., ... & Aucott, J. N. (2026). Pilot study of psilocybin in patients with post-treatment lyme disease. Scientific reports, 16(1), 7497. https://pubmed.ncbi.nlm.nih.gov/41741501/

(2) Aucott, J. N. (2015). Posttreatment lyme disease syndrome. Infectious disease clinics of North America, 29(2), 309–323. https://pubmed.ncbi.nlm.nih.gov/25999226/

(3) Adeyinka, D., Currie, S., & Faraone, N. (2025). Neurobiology of psilocybin: a comprehensive overview and comparative analysis of experimental models. Frontiers in Systems Neuroscience, 19. https://www.frontiersin.org/journals/systems-neuroscience/articles/10.3389/fnsys.2025.1585367/full

(4) Dersch, R., Torbahn, G., & Rauer, S. (2024). Treatment of post‐treatment Lyme disease symptoms—a systematic review. European Journal of Neurology, 31(7), e16293. https://pubmed.ncbi.nlm.nih.gov/38606630/

(5) Werle, I., Guimarães, F. S., Dos Santos, R. G., Hallak, J. E. C., & Bertoglio, L. J. (2026). Ayahuasca modulation of traumatic-like fear memories requires infralimbic cortex BDNF-dependent mechanisms in rats. European Neuropsychopharmacology, 103, 112732. https://pubmed.ncbi.nlm.nih.gov/39756437/